{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002912","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.330081+00:00","generated_at":"2026-06-18T11:28:04.933627+00:00","sec_items":["2.02","2.05","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Coherus Q4 net loss $58.9M, revenue $45.4M; cuts 60 jobs; CSO resigns; UDENYCA AI approved","bullets":["Q4 net revenue $45.4M (down from $73.4M YoY); net loss $58.9M ($0.76 per share) vs $45.7M loss in Q4 2021.","Full year 2022 net revenue $211.0M (down from $326.6M); net loss $291.8M ($3.76 per share).","Workforce reduction of ~60 employees (~20%) to focus on strategic priorities; expects $3.4M restructuring charges.","CSO Vladimir Vexler resigned effective March 10, 2023 (or later at his option), not due to disagreement.","FDA approved UDENYCA autoinjector; toripalimab manufacturing inspection planned for Q2 2023; 2023 opex guidance $315-335M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002912","json":"https://secwatch.observer/filing/0001558370-23-002912.json","markdown":"https://secwatch.observer/filing/0001558370-23-002912.md","text":"https://secwatch.observer/filing/0001558370-23-002912.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/0001558370-23-002912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/chrs-20230302x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:28:04.933627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e192beed5f63794774a7e0cf8a5f58561e1fa880","claim":"Coherus Oncology, Inc. updated its fourth quarter and full year ended December 31, 2022 guidance (reaffirmed).","evidence_excerpt":"On March 6, 2023, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/0001558370-23-002912-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4cf8713537","claim":"Vladimir Vexler resigned as Chief Scientific Officer at Coherus Oncology, Inc..","evidence_excerpt":"On March 2, 2023, Vladimir Vexler, Ph.D., resigned from his role as Chief Scientific Officer of the Company, effective March 10, 2023, unless the effective date is extended to March 31, 2023 at Dr. Vexler’s option.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/0001558370-23-002912-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"c6507e5b73b9a013b4e52c3aed16ecb910f470ea","claim":"Coherus Oncology, Inc. announced a restructuring with charges of approximately $3.4 million (approximately 60 full-time and part-time employees).","evidence_excerpt":"On March 3, 2023, the Company committed to a plan to reduce its workforce (the “Plan”) by approximately 20% to focus resources on strategic priorities including the commercialization of its diversified product portfolio and development of innovative immuno-oncology product candidates. The Company initiated a reduction in force impacting approximately 60 full-time and part-time employees effective March 10, 2023 for most employees. One-time restructuring charges associated with the reduction in force are expected to be approximately $3.4 million, primarily consisting of personnel expenses such as salaries, one-time severance payments, and other benefits.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/0001558370-23-002912-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.4 million"},{"label":"Headcount","value":"approximately 60 full-time and part-time employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}